{
    "pmcid": "10517151",
    "qa_pairs": {
        "How does the study suggest achieving cross-reactivity for SARS-CoV-2 nanobodies?": [
            "Targeting conserved regions of the spike protein",
            "Increasing the size of the nanobodies",
            "Using a cocktail of different nanobodies",
            "Enhancing glycosylation patterns"
        ],
        "What advantage do camelid nanobodies (VHHs) offer in CAR-T cell design according to the study?": [
            "Small size and unique binding capabilities",
            "Ability to bind multiple antigens simultaneously",
            "Long half-life in circulation",
            "High glycosylation levels for stability"
        ],
        "What is the primary target of the camel-derived nanobody-based CAR-T cells discussed in the study?": [
            "B7-H3 protein",
            "SARS-CoV-2 spike protein",
            "PD-L1 protein",
            "HER2 protein"
        ],
        "What method was used in the study to understand CAR-T cell functionality?": [
            "Single-cell transcriptomics and proteomics",
            "Flow cytometry analysis",
            "Western blotting",
            "ELISA assays"
        ],
        "Which domain of the B7-H3 protein is specifically targeted by the nanobody-based CAR-T cells?": [
            "IgC domain",
            "IgV domain",
            "Transmembrane domain",
            "Cytoplasmic domain"
        ]
    }
}